These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25526229)

  • 41. Buprenorphine: revisiting the efficacy of transdermal delivery system.
    Kitzmiller JP; Barnett CJ; Steiner NS; Stoicea N; Kamar N; Luzum JA; Mikulik E; Bergese SD
    Ther Deliv; 2015; 6(4):419-22. PubMed ID: 25996041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study.
    Uberall MA; Mueller-Schwefe GH; Terhaag B
    Curr Med Res Opin; 2012 Oct; 28(10):1617-34. PubMed ID: 22970658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of tramadol in treatment of chronic low back pain.
    Schnitzer TJ; Gray WL; Paster RZ; Kamin M
    J Rheumatol; 2000 Mar; 27(3):772-8. PubMed ID: 10743823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch.
    Stanicic F; Grbic D; Vukicevic D; Zah V
    Pain Manag; 2024 Jan; 14(1):35-48. PubMed ID: 38235537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis.
    Stanicic F; Grbic D; Vukicevic D; Zah V
    J Comp Eff Res; 2024 Aug; 13(8):e230183. PubMed ID: 39012387
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study.
    Gimbel J; Spierings ELH; Katz N; Xiang Q; Tzanis E; Finn A
    Pain; 2016 Nov; 157(11):2517-2526. PubMed ID: 27434505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
    Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
    Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain.
    Uberall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive chronic low back pain: a post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial.
    Nalamachu S; Hale M; Khan A
    J Opioid Manag; 2014; 10(5):311-22. PubMed ID: 25350473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of ischemic pain in patients suffering from peripheral vasculopathy with transdermal buprenorphine plus epidural morphine with ropivacaine vs. epidural morphine with ropivacaine.
    Aurilio C; Pace MC; Passavanti MB; Paladini A; Maisto M; Iannotti M; Pota V; D'amora E; Sansone P; Barbarisi M
    Pain Pract; 2009; 9(2):105-14. PubMed ID: 19019049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
    Hale M; Khan A; Kutch M; Li S
    Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system.
    Kosinski MR; Schein JR; Vallow SM; Ascher S; Harte C; Shikiar R; Frank L; Margolis MK; Vorsanger G
    Curr Med Res Opin; 2005 Jun; 21(6):849-62. PubMed ID: 15969885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M; Ritzdorf I; Brünjes R
    MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
    Canneti A; Luzi M; Di Marco P; Cannata F; Pasqualitto F; Spinoglio A; Reale C
    Minerva Anestesiol; 2013 Aug; 79(8):871-83. PubMed ID: 23558760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.